An interventional study of Mobile Health App for Neuropathic Pain Management in MS in Multiple Sclerosis, sponsored by Meryem Kocaslan Toran. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Meryem Kocaslan Toran · Not applicable, Interventional, and Supportive care
Among 307 studies in Multiple Sclerosis with a site in Turkey — 59 open to participants now, 78 under way, 10 of them phase 3. Multiple Sclerosis · Turkey.
Among the 307 studies in Multiple Sclerosis with a site in Turkey, this one is the 73rd largest by enrollment of the 204 interventional ones, is one of 37 that started in 2025, is one of 155 with no phase, and was the 230th registered.
3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.
This study's enrollment of 56 is above the median of 50 across 2,201 interventional studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →59 of the 307 studies in Multiple Sclerosis with a site in Turkey are open now, in 11 countries. Each count lists the studies.
Of the 430 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 211 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →307 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 37 started in 2025.
Median enrollment 40 across the 204 interventional studies, 60 across the 103 observational. Of the 204 that completed or were terminated, 37 (18%) have results posted.
52 of 307 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Meryem Kocaslan Toran as lead sponsor.
Meryem Kocaslan Toran has 1 study filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
17 of the studies in Multiple Sclerosis with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07137624Hacettepe UniversityMotor Imagery and Action Observation for Gait Function in MS | 2026-11 |
| NCT07571304Istanbul University - CerrahpasaDual-Task Training in Pediatric Multiple Sclerosis | 2026-12-01 |
| NCT07842731Atılım UniversityInvestigation of the Prevalence of Sarcopenia and Dynapenia According to Disease Stage in Patients With Multiple Sclerosis and Evaluation of the Relationship Between Sarcopenia Severity and Clinical and Functional Parameters | 2026-12-10 |
| NCT06777134Berivan Beril KılıçRelationship Between Pelvic Floor Dysfunctions and Lower Limb Strength and Activation in MS Patients | 2026-12-10 |
Among the 307 studies in Multiple Sclerosis with a site in Turkey, from their registry updates:
Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, leading to inflammation, neurodegeneration, and a range of physical and invisible symptoms. Among these, neuropathic pain significantly impairs quality of life but is often overlooked. Neuropathic pain in MS is associated with increased central sensitivity, neuroinflammation, and lifestyle factors such as unhealthy diet, physical inactivity, poor sleep, stress, and smoking. While pharmacological treatments are commonly used, they often provide limited long-term relief and may carry risks such as dependence and side effects.
Growing evidence highlights the importance of non-pharmacological, self-management interventions that promote lifestyle changes. Digital health technologies, particularly mobile health (mHealth) applications, have emerged as accessible tools to support self-management, allowing individuals to take an active role in managing their symptoms and improving their well-being. However, existing mHealth applications often lack scientifically validated content, do not specifically address neuropathic pain, and have limited user-centered design features.
This study aims to develop a self-management-based mHealth application tailored for patients with MS experiencing neuropathic pain. Grounded in Bandura's Social Cognitive Theory, the application will provide educational content, symptom tracking, goal-setting tools, and behavior change strategies covering topics such as nutrition, physical activity, sleep hygiene, stress management, and smoking cessation. The application seeks to improve self-efficacy, reduce pain intensity, and enhance quality of life.
The study will be conducted as a randomized controlled trial. Participants will be randomly assigned to an intervention group (using the mHealth application for eight weeks) or a control group (receiving standard care). Primary outcomes include changes in pain intensity and quality of life. The study hypothesizes that using the mobile application will reduce pain intensity and improve quality of life compared to standard care.
Additionally, the study sets measurable success criteria for the development and evaluation of the application, including expert and user evaluations of content quality, usability, and user satisfaction. The findings aim to contribute to the literature on integrative pain management and demonstrate the
This randomized controlled trial aims to evaluate the efficacy of a self-management-based mobile health application designed for individuals with Multiple Sclerosis (MS) who experience neuropathic pain. Neuropathic pain, affecting up to 58% of MS patients, is associated with neuroinflammation, central sensitization, and oxidative stress, often exacerbated by lifestyle factors such as poor diet, inactivity, poor sleep hygiene, stress, and smoking.
The proposed mobile application is built upon Bandura's Social Cognitive Theory and includes five core modules: self-monitoring, health education, goal-setting, skill-building, and professional support access. The app supports behavior change and provides targeted education on anti-inflammatory nutrition, physical activity, sleep hygiene, stress management, and smoking cessation, aiming to reduce neuropathic pain intensity and improve quality of life.
The app is developed using Flutter/Dart and includes interactive features such as pain diaries, daily goals, reminders, and feedback mechanisms. Educational materials are prepared with input from an interdisciplinary expert panel and validated using DISCERN and HEMDA tools.
The intervention phase will last eight weeks. Patients will be randomized into either the intervention group (app users) or the control group (usual care). Primary outcomes include reduction in pain intensity (VAS) and improvement in quality of life (MSQOL-54). Secondary measures include changes in depression (BDI), insomnia (ISI), fatigue (FSS), and self-management (MSSM).
This project addresses an unmet need for digital, non-pharmacological, evidence-based strategies to support MS patients with neuropathic pain and aims to offer a scalable and accessible solution for long-term self-management.
The criteria were revised on the registry on Oct 27, 2026. See what changed
Inclusion criteria
1 Musculoskeletal surgery within the preceding six months 2 Multiple sclerosis relapse within the preceding month 3 Intravenous or oral treatment within the preceding month 4 Another neurological disorder 5 Visual or auditory impairment affecting completion of the assessments 6 Chronic pain of non-neuropathic origin 7 Peripheral vascular complications due to diabetes or other aetiologies 8 Concurrent participation in a supervised exercise programme, psychological therapy, mind-body practice, acupuncture or invasive pain intervention
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will use the mobile health application for 8 weeks.
Other: Mobile Health App for Neuropathic Pain Management in MS
Participants will receive standard care without the mobile health application.
This intervention is a self-management mobile health application specifically designed for patients with Multiple Sclerosis who experience neuropathic pain. Unlike general symptom tracking apps, this application provides structured educational content on anti-inflammatory nutrition, physical activity, sleep hygiene, stress management, and smoking cessation. It includes goal-setting features, personalized reminders, symptom tracking tools, and feedback mechanisms to promote behavior change and self-efficacy. The intervention is designed based on Social Cognitive Theory, aiming to empower patients to actively manage their pain and improve their quality of life. T
Change in Neuropathic Pain Severity Measured by the Visual Analogue Scale
Neuropathic pain severity was assessed using the Visual Analogue Scale (VAS), ranging from 0 to 10, with higher scores indicating greater pain severity. Change in VAS score from baseline to week 8 was evaluated.
Time frame: Baseline and 8 weeks after intervention start
Change in Physical Health-Related Quality of Life Measured by the Multiple Sclerosis Quality of Life-54
Physical health-related quality of life was assessed using the Physical Health Composite of the Multiple Sclerosis Quality of Life-54 (MSQOL-54). Scores range from 0 to 100, with higher scores indicating better physical health-related quality of life. Change in the Physical Health Composite score from baseline to week 8 was evaluated.
Time frame: Baseline and 8 weeks after intervention start
Change in Mental Health-Related Quality of Life Measured by the Multiple Sclerosis Quality of Life-54
Mental health-related quality of life was assessed using the Mental Health Composite of the Multiple Sclerosis Quality of Life-54 (MSQOL-54). Scores range from 0 to 100, with higher scores indicating better mental health-related quality of life. Change in the Mental Health Composite score from baseline to week 8 was evaluated.
Time frame: Baseline and 8 weeks after intervention start
Change in Fatigue Measured by the Fatigue Severity Scale
Fatigue was assessed using the Fatigue Severity Scale (FSS). Total scores range from 9 to 63, with higher scores indicating greater fatigue severity. Change in FSS score from baseline to week 8 was evaluated.
Time frame: Baseline and 8 weeks after intervention start
Change in Insomnia Severity Measured by the Insomnia Severity Index
Insomnia severity was assessed using the Insomnia Severity Index (ISI). Total scores range from 0 to 28, with higher scores indicating greater insomnia severity. Change in ISI score from baseline to week 8 was evaluated.
Time frame: Baseline and 8 weeks after intervention start
Change in Health-Promoting Lifestyle Behaviours Measured by the Health-Promoting Lifestyle Profile II
Health-promoting lifestyle behaviours were assessed using the Health-Promoting Lifestyle Profile II (HPLP-II). Total scores range from 52 to 208, with higher scores indicating more frequent health-promoting lifestyle behaviours. Change in HPLP-II score from baseline to week 8 was evaluated.
Time frame: Baseline and 8 weeks after intervention start
Change in Self-Management Measured by the Multiple Sclerosis Self-Management Scale
Self-management was assessed using the Multiple Sclerosis Self-Management Scale (MSSM). Total scores range from 24 to 120, with higher scores indicating better self-management. Change in MSSM score from baseline to week 8 was evaluated.
Time frame: Baseline and 8 weeks after intervention start
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2025 to primary completion in Oct 2025, 2 months.
Of 847 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's 2 months is below that.
Counting every sponsor, half of 869 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
Start moved once since we started tracking on Sep 25, 2026: Jul 2025 → Aug 2025, on Oct 27, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.